Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CTMX Stock Alerts

CytomX Therapeutics (CTMX) Short Interest Ratio & Short Volume

CytomX Therapeutics logo
$3.16 -0.06 (-1.71%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CytomX Therapeutics Short Interest Overview

As of July 15, 2026, CytomX Therapeutics (CTMX) had a short interest of 40.32 million shares sold short, representing 24.63% of the public float. This marks a 13.37% increase in short interest since the prior report. The short interest ratio (days to cover) is 10.4, meaning it would take 10.4 days of the average trading volume of 5.20 million shares to cover all short positions.

Current Short Interest
40,322,256 shares
Previous Short Interest
35,567,462 shares
Change Vs. Previous Month
13.37%
Dollar Volume Sold Short
$148.39 million
Short Interest Ratio
10.4 Days to Cover
Last Record Date
July 15, 2026
Outstanding Shares
170,190,000 shares
Short Percent of Float
24.63%
Today's Trading Volume
74,720 shares
Average Trading Volume
5,195,145 shares
Today's Volume Vs. Average
1%
Short Selling CytomX Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for CytomX Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CTMX Short Interest Over Time

CTMX Days to Cover Over Time

CTMX Percentage of Float Shorted Over Time

CytomX Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/202640,322,256 shares $148.39 million +13.4%24.6%10.38 $3.68
6/30/202635,567,462 shares $133.38 million +16.2%21.7%4.32 $3.75
6/15/202630,605,562 shares $93.04 million +6.6%18.7%8.65 $3.04
5/29/202628,719,341 shares $103.39 million -7.8%18.1%9.31 $3.60
5/15/202631,133,767 shares $112.39 million +4.7%19.6%10.32 $3.61
4/30/202629,742,798 shares $125.51 million +8.1%18.7%8.44 $4.22
4/15/202627,517,975 shares $125.48 million +24.9%16.8%5.41 $4.56
3/31/202622,031,153 shares $103.55 million +7.9%13.5%1.14 $4.70
3/13/202620,415,174 shares $95.54 million +8.2%12.5%7.1 $4.68
2/27/202618,864,576 shares $101.30 million +11.2%11.5%8.03 $5.37
2/13/202616,961,879 shares $90.24 million +14.5%10.4%4.66 $5.32
1/30/202614,813,750 shares $84.29 million -8.1%9.0%3.33 $5.69
1/15/202616,118,163 shares $68.50 million -32.0%9.8%7.49 $4.25
12/31/202523,696,755 shares $100.95 million +41.3%14.5%6.56 $4.26
12/15/202516,770,738 shares $69.26 million -2.4%10.2%9.2 $4.13
11/28/202517,187,962 shares $72.36 million -41.4%10.5%7.62 $4.21
11/14/202529,319,732 shares $113.76 million +2.1%19.0%5.59 $3.88
10/31/202528,725,162 shares $102.55 million +1.2%18.6%12.11 $3.57
10/15/202528,400,000 shares $96.84 million -9.5%18.4%7.9 $3.41
9/30/202531,370,000 shares $100.07 million +8.3%N/A9.6 $3.19
9/15/202528,960,000 shares $57.63 million +7.4%N/A10.5 $1.99
8/31/202526,970,000 shares $55.02 million +7.3%17.5%10.1 $2.04
8/15/202525,140,000 shares $48.02 million +4.9%N/A9 $1.91
7/31/202523,960,000 shares $52.47 million +0.4%31.8%4.9 $2.19
7/15/202523,870,000 shares $57.29 million +6.6%N/A4.8 $2.40
6/30/202522,390,000 shares $50.83 million +7.7%29.7%4.5 $2.27
6/15/202520,790,000 shares $57.17 million +9.7%27.6%4.3 $2.75
5/31/202518,960,000 shares $47.78 million +6.9%26.1%4.1 $2.52
5/15/202517,730,000 shares $35.46 million +82.0%24.4%3.5 $2.00
4/30/20259,740,000 shares $7.25 million +1.8%N/A4.3 $0.74
4/15/20259,570,000 shares $6.04 million +2.2%13.1%5.4 $0.63
3/31/20259,360,000 shares $5.95 million +4.0%12.9%5.1 $0.64
3/15/20259,000,000 shares $5.85 million +91.5%12.4%5 $0.65
2/28/20254,700,000 shares $3.18 million +6.8%6.5%2.6 $0.68
2/15/20254,400,000 shares $3.50 million -3.3%6.0%3.9 $0.80
1/31/20254,550,000 shares $3.87 million -1.7%N/A3.6 $0.85
1/15/20254,630,000 shares $3.97 million -3.5%N/A3.6 $0.86
12/31/20244,800,000 shares $4.94 million -13.4%N/A3.9 $1.03
12/15/20245,540,000 shares $6.15 million +26.2%N/A4.8 $1.11
11/30/20244,390,000 shares $4.65 million -1.1%N/A4 $1.06
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad)

Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel

See which companies control the supply chain behind this emerging tech
11/15/20244,440,000 shares $4.04 million -21.7%N/A5.5 $0.91
10/31/20245,670,000 shares $5.65 million -6.6%N/A7.4 $1.00
10/15/20246,070,000 shares $6.80 million -2.9%N/A9.4 $1.12
9/30/20246,250,000 shares $7.38 million -10.5%N/A9.1 $1.18
9/15/20246,980,000 shares $8.59 million -2.4%N/A8.2 $1.23
8/31/20247,150,000 shares $8.44 million -9.2%N/A6.5 $1.18
8/15/20247,870,000 shares $9.37 million +1.7%N/A6 $1.19
7/31/20247,740,000 shares $10.68 million No ChangeN/A2.5 $1.38
7/15/20247,740,000 shares $10.91 million -3.9%N/A1.2 $1.41
6/30/20248,050,000 shares $9.82 million +3.7%N/A1.2 $1.22
6/15/20247,760,000 shares $10.71 million -1.8%N/A1.2 $1.38
5/31/20247,900,000 shares $13.43 million -9.7%N/A1.2 $1.70
5/15/20248,750,000 shares $17.15 million +143.1%N/A1.4 $1.96
4/30/20243,600,000 shares $5.87 million +0.3%N/A0.6 $1.63
4/15/20243,590,000 shares $7.07 million +8.1%N/A4 $1.97
3/31/20243,320,000 shares $7.24 million -6.0%N/A3.8 $2.18
3/15/20243,530,000 shares $7.31 million +115.2%N/A4.1 $2.07
2/29/20241,640,000 shares $4.02 million +26.2%N/A2.2 $2.45
2/15/20241,300,000 shares $1.95 million +4.0%N/A2.8 $1.50
1/31/20241,250,000 shares $1.91 million -5.3%N/A4.2 $1.53
1/15/20241,320,000 shares $2.28 million -0.8%N/A4.4 $1.73
12/31/20231,330,000 shares $2.06 million +35.5%N/A4.9 $1.55
12/15/2023981,600 shares $1.38 million -26.8%N/A5 $1.41
11/30/20231,340,000 shares $1.86 million +0.8%N/A7.5 $1.39
11/15/20231,330,000 shares $1.72 million +5.6%N/A8 $1.29
10/31/20231,260,000 shares $1.39 million -18.2%N/A7 $1.10
10/15/20231,540,000 shares $1.93 million -9.9%N/A8.5 $1.25
9/30/20231,710,000 shares $2.21 million -23.0%N/A9.5 $1.29
9/15/20232,220,000 shares $3.06 million +2.3%N/A8.2 $1.38
8/31/20232,170,000 shares $3.26 million +5.9%N/A7.5 $1.50
8/15/20232,050,000 shares $3.26 million -21.5%N/A6.5 $1.59
7/31/20232,610,000 shares $4.54 million -3.0%4.0%7 $1.74
7/15/20232,690,000 shares $4.90 million +13.0%4.1%6.8 $1.82
6/30/20232,380,000 shares $4.09 million No Change3.7%5.3 $1.72
6/15/20232,380,000 shares $3.71 million +4.4%3.7%4.5 $1.56
5/31/20232,280,000 shares $3.90 million +7.0%3.5%3.4 $1.71
5/15/20232,130,000 shares $3.88 million -13.4%3.3%2.8 $1.82
4/30/20232,460,000 shares $4.01 million +9.3%3.8%2.8 $1.63
4/15/20232,250,000 shares $3.74 million +40.6%3.5%2 $1.66
3/31/20231,600,000 shares $2.42 million -14.9%2.5%1 $1.51
3/15/20231,880,000 shares $3.82 million +48.0%2.9%0.8 $2.03
2/28/20231,270,000 shares $2.73 million -8.0%2.0%0.5 $2.15
2/15/20231,380,000 shares $3.20 million -13.8%2.1%0.5 $2.32
1/31/20231,600,000 shares $4.32 million -43.3%2.5%0.5 $2.70
1/15/20232,820,000 shares $8.07 million +433.7%4.3%1 $2.86
12/30/2022528,400 shares $845.44 thousand -64.1%0.8%0.2 $1.60
12/15/20221,470,000 shares $2.34 million -26.1%2.3%1.1 $1.59
11/30/20221,990,000 shares $3.46 million +103.7%3.1%1.6 $1.74
11/15/2022977,100 shares $1.16 million -2.0%1.5%0.8 $1.19
10/31/2022997,400 shares $1.31 million -6.8%1.6%2 $1.31
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad)

Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel

See which companies control the supply chain behind this emerging tech
10/15/20221,070,000 shares $1.52 million -10.8%1.7%1.6 $1.42
9/30/20221,200,000 shares $1.74 million +2.6%1.9%1.3 $1.45
9/15/20221,170,000 shares $1.94 million +30.9%1.9%0.7 $1.66
8/31/2022894,100 shares $1.34 million -14.0%1.4%0.5 $1.50
8/15/20221,040,000 shares $1.80 million -21.2%1.7%0.6 $1.73
7/31/20221,320,000 shares $1.89 million +1.5%2.1%0.7 $1.43
7/15/20221,300,000 shares $1.95 million +10.2%2.1%0.7 $1.50
6/30/20221,180,000 shares $2.16 million -67.7%1.9%0.7 $1.83
6/15/20223,650,000 shares $6.28 million -4.5%5.9%3.2 $1.72
5/31/20223,820,000 shares $6.15 million -5.5%6.1%3.5 $1.61
5/15/20224,040,000 shares $7.11 million +6.3%6.5%3.8 $1.76
4/30/20223,800,000 shares $6.50 million +37.7%6.2%3.9 $1.71
4/15/20222,760,000 shares $6.38 million -29.6%4.5%3.2 $2.31
3/31/20223,920,000 shares $10.47 million +2.6%6.4%4.4 $2.67
3/15/20223,820,000 shares $11.38 million No Change6.3%3.2 $2.98
2/28/20223,820,000 shares $14.63 million -2.1%6.3%3.4 $3.83
2/15/20223,900,000 shares $15.91 million +11.4%6.4%3.2 $4.08
1/31/20223,500,000 shares $16.10 million -5.4%5.6%2.7 $4.60
1/15/20223,700,000 shares $14.62 million +19.4%5.9%2.9 $3.95
12/31/20213,100,000 shares $13.42 million -22.3%5.0%2.6 $4.33
12/15/20213,990,000 shares $26.65 million +9.0%6.4%3.6 $6.68
11/30/20213,660,000 shares $24.19 million -21.8%5.9%5.3 $6.61
11/15/20214,680,000 shares $33.98 million -3.3%7.5%7.6 $7.26
10/29/20214,840,000 shares $28.70 million +7.6%7.7%8.1 $5.93
10/15/20214,500,000 shares $23.13 million -7.4%7.2%8.1 $5.14
9/30/20214,860,000 shares $24.74 million -7.3%7.7%8.1 $5.09
9/15/20215,240,000 shares $26.04 million -11.2%8.3%7.6 $4.97
8/31/20215,900,000 shares $30.21 million -11.7%9.4%8.6 $5.12
8/13/20216,680,000 shares $32.40 million -4.4%10.6%9.2 $4.85
7/30/20216,990,000 shares $37.82 million +5.1%10.9%9.3 $5.41

CTMX Short Interest - Frequently Asked Questions

Short interest is the volume of CytomX Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 40,322,256 shares of CTMX short. 24.63% of CytomX Therapeutics' shares are currently sold short. Learn More on CytomX Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTMX shares currently have a short interest ratio of 10.4. Learn More on CytomX Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 24.63% of CytomX Therapeutics' floating shares are currently sold short.

CytomX Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totaling 40,322,256 shares, an increase of 13.4% from the previous total of 35,567,462 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

24.63% of CytomX Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to CytomX Therapeutics: Nurix Therapeutics, Inc. (18.57%), Vericel Corporation (9.75%), Agios Pharmaceuticals, Inc. (11.78%), Biohaven Ltd. (14.91%), Kailera Therapeutics, Inc. (4.95%), Hemab Therapeutics Holdings, Inc. (3.55%), Zai Lab Limited Unsponsored ADR (5.87%), Pharvaris N.V. (1.97%), Palvella Therapeutics, Inc. (18.33%), Mesoblast Limited (2.98%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.09 billion), Invesco QQQ ($48.11 billion), iShares Russell 2000 ETF ($23.61 billion), Sandisk Corporation ($12.69 billion), Nebius Group N.V. ($12.18 billion), Western Digital Corporation ($11.95 billion), SPDR S&P Biotech ETF ($11.73 billion), Quhuo Limited Sponsored ADR ($9.74 billion), VanEck Semiconductor ETF ($9.57 billion), and Financial Select Sector SPDR Fund ($8.43 billion). View all of the most shorted stocks.

Short selling CTMX is an investing strategy that aims to generate trading profit from CytomX Therapeutics as its price is falling. CTMX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for CytomX Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CTMX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTMX, twice per month. The most recent reporting period available is July, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CTMX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:CTMX) was last updated on 7/24/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel